Governance

Our governance committee consists of leadership from across our network partner institutions. These members were pivotal in establishing the SAN and continue to provide guidance and feedback toward strategic growth and operation.

Our governance facilitates open communication between leadership within our network, ensuring discussions involve the voices of all partners. These members also helped to establish administrative workflows and communication pipelines that streamline specimen request and acquisition within our network. These leaders have also been key drivers in the development of standardized material and data transfer agreements that ease and accelerate our specimen transfer process.

We thank our governance committee members and partner organizations for their founding guidance, involvement, and continued support.

BC Cancer/University of British Columbia

Sam Leung

Samuel Leung, MS

Data Manager, OVCARE
Database and Information Technology Manager, Genetic Pathology Evaluation Centre

Mr. Sam Leung is a Data Manager at OVCARE and the Database and Information Technology Manager at the Genetic Pathology Evaluation Centre (GPEC). OVCARE’s mission is to enhance ovarian cancer research in British Columbia with the goal of reducing incidence and improving health outcomes for women facing this disease. GPEC is a collaborative group with the goal of improving the management of cancer patients through the rapid clinical validation of prognostic and predictive cancer biomarkers. Sam’s areas of interest include biobanking software and data management, digital pathology, and statistical analysis. Mr. Leung earned a Master of Science from the University of Victoria, Canada, majoring in Computer Science.


 

Aline Talhouk

Aline Talhouk, PhD

Assistant Professor, Obstetrics, BC Cancer/University of British Columbia
Director, Data Science and Informatics, OVCARE

Dr. Talhouk is an assistant professor in the department of Obstetrics & Gynecology in the Faculty of Medicine at the University of British Columbia. She is also the director of data science and informatics at OVCARE, BC’s ovarian and gynecological cancer research program. She completed her PhD in Statistics at the University of British Columbia in 2013 with a focus on computational statistics and machine learning. Since then, she has been working on developing and implementing predictive models to improve patient care in women’s health and oncology. Her research focus also includes the ethics of data sharing and privacy in the era of digital health and AI modeling.


Benaroya Research Institute

Jane Buckner

Jane Buckner, MD

President, Benaroya Research Institute
Director, Translational Research Core, Benaroya Research Institute
Affiliate Professor, Immunology, University of Washington
Affiliate Professor, Medicine, Division of Rheumatology, University of Washington
Partner, Allen Institute for Immunology

Dr. Jane Buckner’s interdisciplinary research combines genetics, immunology and clinical medicine to advance our understanding of the causes of autoimmune diseases including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and relapsing polychondritis. Her research goal is to expand our understanding of each disease by identifying the common features that cause them. Her research group has approached this question through the study of genetic risk variants associated with autoimmunity, analysis of regulatory and effector adaptive responses in samples from patients with autoimmune disease and targeted analysis of autoreactive CD4 T cells from patients with autoimmunity. Dr. Buckner has published more than 100 peer-reviewed papers, and is currently funded by the National Institutes of Health and the Leona M. and Harry B. Helmsley Charitable Trust. Dr. Buckner received her bachelor’s degree in chemistry from Carleton College, and her medical degree from Johns Hopkins School of Medicine. She has been honored by the American College of Rheumatology, having received both their Senior Rheumatology Scholar award, and their Arthritis Investigator Award.

Gina Marchesini

Gina Marchesini, MPA

Translational Research Program Manager, Benaroya Research Institute

Ms. Gina Marchesini is the Translational Research Core Administrative Manager at Benaroya Research Institute. Gina is a proven administrative and clinical operations manager in the medical and social science research industry. She is able to conceptualize, execute, and communicate program vision, while also managing milestones and motivating diverse groups. Gina has a demonstrated history of integrity and strong organizational, managerial, and analytical skills.

 

Lynn Rose

Lynn Rose, PhD

Chief of Scientific Administration, Benaroya Research Institute

Dr. Lynn Rose is the Director of Scientific Administration at Benaroya Research Institute. Lynn has more than 30 years of experience in biomedical research, including positions in both academia and industry. Her industry experience has included direct responsibility for preclinical, clinical and regulatory programs. At BRI, Dr. Rose has parlayed her extensive experience in biomedical research to foster strong alliances with corporate, government, and academic partners. She is charged with making sure that researchers have the tools to make progress in new areas, and when cancer-autoimmunity links began to emerge, she decided the institute needed a collection of blood and tissue samples from cancer patients. Dr. Rose secured funding and started the Virginia Mason and Benaroya Research Institute Tumor Repository (VM BRITE), focused on understanding the link between cancer and autoimmunity.


Fred Hutch

Elizabeth Boyd

Elizabeth Boyd, PhD

Vice President, Research Administration & Faculty Affairs, Cheif Ethics & Compliance Officer, Fred Hutch

Dr. Elizabeth Boyd is Vice President of Research Administration and Faculty Affairs and the Chief Ethics & Compliance Officer at Fred Hutch. Dr. Boyd has held several leadership positions in the University of California system, including Chief Ethics and Compliance Officer at University of California San Francisco and Executive Director of Research Compliance at the University of California Office of the President. She is a medical sociologist and bioethicist and has lectured nationally on conflicts of interest, ethical issues in clinical trials, responsible conduct of research, practice guideline development, peer review and publication ethics, and direct-to-consumer drug marketing. Dr. Boyd received her postdoctoral training at the Institute for Health Policy Studies (UCSF), served as adjunct faculty in the Department of Clinical Pharmacy, and served as a consultant to many policy groups, including the Institute of Medicine, NIH/Office of Research Integrity joint program in research integrity, and the World Health Organization. She has a PhD in Medical Sociology from UCLA. Her research interests include clinical decision-making, patient-provider interaction, research ethics, and policy implementation.

Rachel Galbraith

Rachel Galbraith, MPH

Operations Director, Seattle Translational Tumor Research, Fred Hutch

Ms. Rachel Galbraith is the Operations Director for Seattle Translational Tumor Research (STTR). Rachel leads the STTR team which brings together 500+ faculty spanning oncology research efforts at Fred Hutch, UW Medicine, Seattle Cancer Care Alliance, Seattle Children’s Research Institute and several other Seattle-area translational research institutions. Her work enhances collaborative scientific efforts, reduces barriers such as access to clinical specimens, data, and technology that will speed research and improve cancer prevention, treatment and detection. This work is informed by skill set which includes molecular genetics, public health and cell biology, and 5+ years facilitating translational research across a diverse network. Leveraging this expertise, she builds strategy and programs to support and speed this work.

Eric Holland

Eric Holland, MD, PhD

Senior Vice President and Director, Human Biology Division, Fred Hutch
Director, Seattle Translational Tumor Research, Fred Hutch

Dr. Eric Holland is the Senior Vice President and Director of the Human Biology Division at Fred Hutch and the Director of Seattle Translational Tumor Research. Dr. Holland is a world-renowned physician-scientist who combines compassionate patient care with exacting laboratory research to discover more effective treatments for brain tumors. As a neurosurgeon, he specializes in caring for patients with glioblastomas, the most common malignant brain tumors in adults. Dr. Holland is committed to finding targeted treatment options for this aggressive cancer, which currently has few effective therapies. He continues to foster productive collaborations to spark discovery and advance precision oncology. Dr. Holland believes Oncoscape has the potential to transform patient treatment. Using this tool, researchers can now begin to group tumors by their genetic profiles to help physicians select therapies likely to work best for each patient.

Kathi Malone

Kathi Malone, PhD

Program Head and Professor, Epidemiology Program, Public Health Sciences Division, Fred Hutch
Research Professor, Epidemiology, School of Public Health, University of Washington

Dr. Kathi Malone is a Professor in the Public Health Sciences Division and Head of the Epidemiology Program at Fred Hutch. Dr. Malone studies the causes of breast cancer and factors that influence how a patient will fare after treatment. Dr. Malone has conducted extensive research on BRCA1/2 genetic mutations. She led the first population-based study of the prevalence and predictors of BRCA1/2 mutations in young women and subsequent investigations of understudied groups including African Americans and women with contralateral breast cancer. Identifying the multifactorial determinants of adverse outcomes after breast cancer in order to develop clinically relevant prediction and prevention strategies is a current focus. Using large-scale population-based designs that include interviews, medical record reviews, and tumor collection/molecular analyses, her group seeks to characterize the personal, lifestyle, clinical, and tumor-based determinants of breast cancer recurrence and second primary cancers.

Traci Rieckmann

Traci Rieckmann, PhD

Business Development & Strategic Planning Consultant, Fred Hutch
Chief Operating Officer, GreenField Health

Dr. Traci Rieckmann is a Business Development & Strategic Planning Consultant at Fred Hutch and the Chief Operating Officer at GreenField Health. Traci is a visionary COO, executive leader, and research scientist with PhD credentials and a demonstrated track record of leadership within Life Science, Biotechnology, Higher Education & Medical Research Institutions. Her background includes extensive experience partnering with executive and clinical leaders to foster operational excellence, galvanize innovation, increase funding, and enhance market share and revenue growth. Dr. Rieckmann’s areas of focus include the delivery of integrated, evidence-based medical services and behavioral health care — as well as the coordination of biobehavioral health, psychiatry studies, and health policy clinical trials. She has a unique multi-disciplinary background that spans private-sector business leadership, academic positions, clinical practice expertise, and principal investigator/research roles with top organizations such as Fred Hutchinson Cancer Research Institute and Oregon Health & Science University. Dr. Rieckmann received her Doctor of Philosophy in Counseling Psychology from the University of Utah in 2001, and her Master of Science in Health Promotion & Education from the University of Utah in 1994.

Cecilia Yeung

Cecilia Yeung, MD

Associate Professor, Clinical Research Division, Fred Hutch
Associate Professor, Pathology, University of Washington
Pathologist, Seattle Cancer Care Alliance

Dr. Cecilia Yeung is an Associate Professor in the Clinical Research Division at Fred Hutch, Associate Professor of Pathology at the University of Washington, and a Pathologist at the Seattle Cancer Care Alliance Clinical Pathology Lab. Dr. Yeung studies blood diseases and specializes in the molecular traits of myelodysplastic syndromes. Her team uses whole genome interrogation methods such as genomic array and massive parallel sequencing to tease out genes that may affect patient prognosis or serve as potential targets for therapy. Dr. Yeung also diagnoses diseases that can arise after transplant. She has a particular interest in graft-vs.-host disease and infectious diseases seen in the lungs of blood cell transplant patients. As a researcher, Dr. Yeung hopes to discover useful biomarkers which may aid in diagnosis and prognosis and guide future therapies. She earned her M.D. from Penn State. As a part of the UW's Pathology faculty, she heads efforts to expand molecular pathology education. She is active in the Molecular Genetics Fellowship and chair of the Clinical Competency Committee.


Legacy Research Institute

Joseph Frascelli

Joseph Frascella, PhD

Vice President of Research, Legacy Research Institute

Dr. Joseph Frascella is the Vice President of Research at the Legacy Research Institute (LRI) within Legacy Health. Dr. Frascella joined LRI with a wealth of experience, most recently as the senior science advisor to the director of the National Institute on Drug Abuse (NIDA) within the National Institutes of Health, and on a special assignment as a Senior Research Scientist at the University of Maryland, Baltimore County (UMBC) working in the Office of the Vice President for Research. Prior to this position, he served for several years as the Director of the Division of Clinical Neuroscience and Behavioral Research at NIDA, leading broad basic and clinical drug abuse/addiction and research training programs in neuroscience, human development, and behavioral treatment. Previously, he served in other extramural research positions at NIDA, including Branch Chief and Program Director for NIDA’s programs in basic and clinical neurosciences. Dr. Frascella holds a PhD in experimental psychology and neuroscience and a Master of Science in experimental psychology from Brown University. Joseph believes that building collaborative interdisciplinary teams and multidimensional partnerships as well as harnessing the power of big data analytics are necessary for forging novel and transformative research.


Oregon Health & Science University

Christopher Corless

Christopher Corless, MD, PhD

Chief Medical Officer, Knight Diagnostic Laboratories, Oregon Health & Science University

Dr. Christopher Corless is the Chief Medical Officer (CMO) for Knight Diagnostic Laboratories housed at the Oregon Health & Science University. Chris has proven expertise in molecular pathology, particularly in oncology-related applications, including test development and validation. As the CMO for an academically-based molecular diagnostics laboratory, he has experience in laboratory management and have served as a consultant to a number of companies, including Novartis, Pfizer, Roche/Genentech, Roche/Ventana, Asuragen, Cepheid, Leica Biosystems, and ThermoFisher. Dr. Corless has over 20 years of experience as a staff pathologist in academic practice, with a particular interest in GI and GU pathology. His specialties include next-generation sequencing, real-time quantitative PCR, immunohistochemistry, pyrosequencing, high resolution melting curve analyses, and working with nucleic acids from FFPE tissue.

Danielle Galipeau

Danielle Galipeau

Operations Supervisor, Knight BioLibrary, Oregon Health & Science University

Ms. Danielle Galipeau has served as Operations Supervisor for the OHSU Knight BioLibrary since 2018, overseeing the acquisition, storage, and distribution of biospecimens in support of academic and commercial research enterprises. She started her career at OHSU in 2007 as a research assistant and worked in various labs on campus before joining the BioLibrary in 2014. Prior to working at OHSU, she worked at The American Red Cross National Testing Lab as a Laboratory Assistant and at Alpha Therapeutics Corporation as an Operations Manager. She brings close to 20 years’ experience in management, research, biobanking and quality control. Ms. Galipeau earned a Bachelor of Science from University of Oregon, majoring in Biology.


Swedish Cancer Institute

Anna Berry

Anna Berry, MD

Scientific Director, Personalized Medicine Program, Swedish Cancer Institute
Director, Molecular Pathology, CellNetix

Dr. Anna Berry is the Scientific Director of the Personalized Medicine Program at the Swedish Cancer Institute and the Director of Molecular Pathology at CellNetix. She is a graduate of the University of Nebraska Medical Center, and completed her post-graduate training at SUNY Upstate Medical University, the Medical College of Virginia, and the National Cancer Institute. Dr. Berry is Board Certified in Molecular Genetic Pathology, Cytopathology, Anatomic Pathology and Clinical Pathology, and served previously as the Director of Molecular Pathology and the Director of the Molecular Genetic Pathology fellowship training program at UCSF. Her clinical focus is making genomic technologies accessible to patients, and integrating genomic data into patient care. She serves on several national committees, including the Personalized Healthcare Committee of the College of American Pathologists, participates in several national genomics task forces. Dr. Berry has given invited lectures and has taught CME courses at many locations across the country, as well as on-line.

Charles Drescher

Charles Drescher, MD

Gynecologic Oncologist, Swedish Cancer Institute
Member, Public Health Sciences Division, Fred Hutch

Dr. Charles Drescher is a Gynecologic Oncologist at Swedish Cancer Institute and a Member of the Public Health Sciences Division at Fred Hutch. He is a practicing gynecologic oncologist and surgeon who researches gynecological cancers through Fred Hutch’s Translational and Outcomes Research Group. He has extensive experience in collecting and processing tissues and blood specimens from ovarian cancer patients, which are banked for use in research studies. In addition, he has led efforts to discover molecular targets for ovarian cancer prognosis and therapy. As an expert in gynecological oncology, Dr. Drescher is actively involved in many ovarian cancer research organizations, including the Gynecological Oncology Group, the Puget Sound Oncology Consortium and the Pacific Ovarian Cancer Research Consortium. He is also the former medical director of the Marsha Rivkin Center for Ovarian Cancer Research at Swedish Medical Center.


UW Medicine

Kelly Smith

Kelly Smith, MD, PhD

Professor, Department of Pathology, University of Washington
Director, NW BioTrust/BioSpecimen
Director, Renal Pathology Service
Director, Pathology Residency Training Program, University ofWashington

Dr. Kelly Smith is a Professor in the Department of Pathology and Director of NW BioTrust/BioSpecimen, which is based in the Department of Pathology at the University of Washington, and a collaboration between UW Medicine, Fred Hutch, and Seattle Cancer Care Alliance. Dr. Smith is a board-certified anatomic pathologist with subspecialty expertise in renal, cardiovascular and autopsy pathology. Dr. Smith has been conducting research in immunology, both adaptive and innate immunity, for over twenty years, with emphasis on mucosal innate immunity and the factors that regulate colonization, inflammation and protective immune responses. More recently, he has been expanding his research interests and leveraging his expertise as a pathologist and basic scientist to use advanced technologies to provide novel insight into human disease. He has close collaborations with proteomics and genomics laboratories to interrogate human tissues using state of the art technologies. His lab’s current efforts are focused on understanding disease processes that he encounters on a daily basis as an anatomic pathologist, with a primary focus on medical kidney diseases. In addition, in his current position as director of Northwest BioSpecimen (NWB), he oversees the procurement and distribution of human biospecimens to the Seattle research community, which supports a vast array of basic science, translational studies and clinical trials for our researchers and patient populations. He is committed to increasing access to human biospecimens, which are essential resources needed to develop new models of human disease, and better means to diagnose and treat human diseases. He earned his medical degree and doctorate from the University of Iowa in 1996, and is a member of several organizations, including the United States and Canadian Academy of Pathology, the Renal Pathology Society and the American Society of Nephrologists.